(Q38109432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Low-grade serous carcinoma: new concepts and emerging therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

low-grade serous carcinoma

0 references

author

Robert C. Bast

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Kwong K. Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5

David M Gershenson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Ignacio Romero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Charlotte C Sun

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

23 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

660-666

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Low-grade serous ovarian cancer: a unique disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The heterogeneity of epithelial ovarian cancer: getting it right

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian carcinomas with transitional cell carcinoma pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Histopathologic grading of ovarian carcinoma: a review and proposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Classification and Staging of Malignant Tumours in the Female Pelvis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The pathology of and controversial aspects of ovarian borderline tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Epidemiology of low-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Serous borderline tumors of the ovary with noninvasive peritoneal implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian tumors in a cohort of infertile women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Treatment for Fertility and Risk of Ovarian Tumors of Borderline Malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Diverse tumorigenic pathways in ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Biochip for K-ras Mutation Screening in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

PIK3CA mutations in advanced ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Low-grade serous carcinomas of the ovary contain very few point mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Genomic copy number variation, human health, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Gene amplification in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Ovarian cancer metastasis: integrating insights from disparate model organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Incessant ovulation--a factor in ovarian neoplasia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Tubal origin of 'ovarian' low-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

The origin of ovarian carcinomas: a unifying hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Recurrent micropapillary serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.021

10.1016/J.YGYNO.2013.05.021

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23707670%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference